Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: A review

Neurochemical Research

Volumn 33, Issue 1, 2008, Pages 204-219

  Kitanaka, Junichi ^a   Kitanaka, Nobue ^a   Takemura, Motohiko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Amphetamine withdrawal; Animal model; Dysphoria; Gene expression; Monoaminergic transmission; Treatment regimen

Indexed keywords

4 AMINOBUTYRIC ACID; ACYLTRANSFERASE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; CONNEXIN 36; DAT ENZYME; DOPAMINE; MESSENGER RNA; MONOAMINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NORADRENALIN; PROTEIN FOS; SNARE PROTEIN; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANHEDONIA; ANXIETY DISORDER; AUTOPSY; CLINICAL FEATURE; DEPRESSION; DRUG DEPENDENCE; DRUG WITHDRAWAL; DYSPHORIA; GENE EXPRESSION; IMPULSIVENESS; LATENT INHIBITION; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD BEHAVIOR; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW; SELF STIMULATION; SUICIDAL IDEATION;

AMPHETAMINES; ANIMALS; MODELS, ANIMAL; MOOD DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; RODENTIA;

EID: 36949000644     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9409-7     Document Type: Review

References (120)

1. van Rossum JM (1970) Mode of action of psychomotor stimulant drugs: significance of dopamine in locomotor stimulant action. Int Rev Neurobiol 12:307-383
2. Groves PM, Rebec GV (1976) Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. Annu Rev Psychol 27:91-127
3. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278
4. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 32:639-677
5. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433
6. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247-291
7. Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6:243-251
8. Volkow ND, Fowler JS, Wang G-J, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9:557-569
9. Gardner EL (2004) Brain-reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse: a comprehensive textbook, 4th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 48-97
10. National Institute on Drug Abuse (2004) NIDA InfoFacts: methamphetamine. Accessed 15 Dec 2006 URL: http://www.nida.nih.gov/infofacts/methamphetamine.html
11. Kosman ME, Unna DR (1968) Effects of chronic administration of the amphetamines and other stimulants on behavior. Clin Pharmacol Ther 9:240-254
12. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58
13. Everitt BJ, Robbins TW (2004) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neurosci 8:1481-1489
14. Kramer JC, Fischman VS, Littlefield DC (1967) Amphetamine abuse: pattern and effects of high doses taken intravenously. JAMA 201:305-309
15. Randrup A, Munkvad I (1967) Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl) 11:300-310
16. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198
17. Sato M (1992) A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann NY Acad Sci 654:160-170
18. Gawin FH, Ellinwood EH Jr (1988) Cocaine and other stimulants: actions, abuse, and treatment. New Eng J Med 318:1173-1182
19. Lago JA, Kosten TR (1994) Stimulant withdrawal. Addiction 89:1477-1481
20. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC
21. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ (1996) The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 66:17-31
22. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135-174
23. Kosten TR, Markou A, Koob GF (1998) Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis 186:737-745
24. Watson R, Hartmann E, Schildkraut JJ (1972) Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. Am J Psychiatry 129:263-269
25. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005) The nature, time course and severity of methamphetamine withdrawal. Addiction 100:1320-1329
26. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH (2000) Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 12:480-484
27. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P (2001) Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 4:CD003022
28. Cox D, Bowers R, McBride A (2004) Reboxetine may be helpful in the treatment of amphetamine withdrawal. Br J Clin Pharmacol 58:100-101
29. Kongsakon R, Papadopoulos KI, Saguansiritham R (2005) Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 20:253-256
30. Molina JD, de Pablo S, Lopez-Munoz F, Alamo C, Blasco-Fontecilla H, Gonzalez-Parra S (2006) Monotherapy with reboxetine in amphetamine withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 30:1353-1355
31. Winchel RM, Stanley M (1991) Self-injurious behavior: a review of the behavior and biology of self-mutilation. Am J Psychiatry 148:306-317
32. Dopheide JA (2006) Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 63:233-243
33. Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242:715-723
34. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
35. Booij L, Van der Does AJW, Riedel WJ (2003) Monoamine depletion in psychiatric and healthy population: review. Mol Psychiatry 8:951-973
36. Kokkinidis L, Zacharko RM, Anisman H (1986) Amphetamine withdrawal: a behavioral evaluation. Life Sci 38:1617-1623
37. Murphy CA, Fend M, Russig H, Feldon J (2001) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 6:1247-1256
38. Russig H, Pezze M-A, Nanz-Bahr NI, Pryce CR, Feldon J, Murphy CA (2003) Amphetamine withdrawal does not produce a depressive-like state in rats as measured by three behavioral tests. Behav Pharmacol 14:1-18
39. Post RM (1980) Intermittent versus continuous stimulation: effect of time interval on the development of sensitization. Life Sci 26:1275-1282
40. Eison MS, Eison AS, Iversen SD (1983) Two routes of continuous amphetamine administration induce different behavioral and neurochemical effects in the rat. Neurosci Lett 39:313-319
41. Robinson TE, Camp DE (1987) Long-lasting effects of escalating doses of d-amphetamine on brain monoamines, amphetamine-induced stereotyped behavior and spontaneous nocturnal locomotion. Pharmacol Biochem Behav 26:821-827
42. Lin D, Koob GF, Markou A (2000) Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol Biochem Behav 65:407-417
43. Kuhar MJ, Pilotte NS (1996) Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 17:260-264
44. White FJ, Kalivas PW (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153
45. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nature Rev Neurosci 2:119-128
46. Lu L, Dempsey J, Liu SY, Bossert JM, Shaham Y (2004) A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J Neurosci 24:1604-1611
47. Gorelick DA, Gardner EL, Xi Z-X (2004) Agents in development for the management of cocaine abuse. Drugs 64:1547-1573
48. Paulson PE, Camp DM, Robinson TE (1991) Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berl) 103:480-494
49. Russig H, Murphy CA, Feldon J (2005) Behavioural consequences of withdrawal from three different administration schedules of amphetamine. Behav Brain Res 165:26-35
50. Schindler CW, Persico AM, Uhl GR, Goldberg SR (1994) Behavioral assessment of high-dose amphetamine withdrawal: importance of training and testing conditions. Pharmacol Biochem Behav 49:41-46
51. Lynch MA, Leonard BE (1978) Effect of chronic amphetamine administration on the behaviour of rats in the open field apparatus: reversal of post-withdrawal depression by two antidepressants. J Pharm Pharmacol 30:798-799
52. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 23:113-126
53. Schreiber H, Bell R, Conely L, Kufner M, Palet J, Wright L (1976) Diminished reaction to a novel stimulus during amphetamine withdrawal in rats. Pharmacol Biochem Behav 5:687-690
54. Bisagno V, Ferguson D, Luine VN (2005) Chronic D-amphetamine induces sexually dimorphic effects on locomotion, recognition memory, and brain monoamines. Pharmacol Biochem Behav 74:859-867
55. Belcher AM, O'Dell SJ, Marshall JF (2005) Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 30:2026-2034
56. Lubow RE (1973) Latent inhibition. Psychol Bull 79:398-407
57. Russig H, Murphy CA, Feldon J (2002) Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765-777
58. Russig H, Murphy CA, Feldon J (2003) Prepulse inhibition during withdrawal from an escalating dosage schedule of amphetamine. Psychopharmacology (Berl) 169:340-353
59. Weiner I, Lubow RE, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl) 83:194-199
60. Peleg-Raibstein D, Sydekum E, Feldon J (2006) Differential effects on prepulse inhibition of withdrawal from two different repeated administration schedules of amphetamine. Int J Neuropsychopharmacol 9:737-749
61. Doty RW (1969) Electrical stimulation of the brain in behavioral context. Annu Rev Psychol 20:189-320
62. Leith NJ, Barrett RJ (1976) Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia (Berl) 46:19-25
63. Simpson DM, Annau Z (1977) Behavioral withdrawal following several psychoactive drugs. Pharmacol Biochem Behav 7:59-64
64. Kokkinidis L, Zacharko RM (1980) Response sensitization and depression following long-term amphetamine treatment in a self-stimulation paradigm. Psychopharmacology (Berl) 68:73-76
65. Kokkinidis L, Zacharko RM, Predy PA (1980) Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharmacol Biochem Behav 13:379-383
66. Cassens G, Actor C, Kling M, Schildkraut JJ (1981) Amphetamine withdrawal: effects on threshold of intracranial reinforcement. Psychopharmacology (Berl) 73:318-322
67. Wise RA, Munn E (1995) Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology (Berl) 117:130-136
68. Lin D, Koob GF, Markou A (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl) 145:283-294
69. Barr AM, Zis AP, Phillips AG (2002) Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats. Psychopharmacology (Berl) 159:196-202
70. Cryan JF, Hoyer D, Markou A (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54:49-58
71. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473-2476
72. Kornetsky C, Esposito RU (1981) Reward and detection thresholds for brain stimulation: dissociative effects of cocaine. Brain Res 209:496-500
73. Barr AM, Fiorino DF, Phillips AG (1999) Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol Biochem Behav 64:597-604
74. Pezze MA, Feldon J, Murphy CA (2002) Increased conditioned fear response and altered balance of dopamine in the shell and core of the nucleus accumbens during amphetamine withdrawal. Neuropharmacology 42:633-643
75. Russig H, Durrer A, Yee BK, Murphy CA, Feldon J (2003) The acquisition, retention and reversal of spatial learning in the Morris water maze task following withdrawal from an escalating dosage schedule of amphetamine in Wistar rats. Neuroscience 119:167-179
76. Peterson JD, Wolf ME, White FJ (2003) Impaired DRL 30 performance during amphetamine withdrawal. Behav Brain Res 143:101-108
77. Ellinwood EH Jr, Kilbey MM (1977) Chronic stimulant intoxication models of psychosis. In: Hanin I, Usdin E (eds) Animal models in psychiatry and neurology. Pergamon Press, New York, pp 61-74
78. Kitanaka J, Kitanaka N, Takemura M (2006) Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights 1:19-28. URL: http://www.la-press.com/index.php
79. Swerdlow NR, Hauger R, Irwin M, Koob GF, Britton KT, Pulvirenti L (1991) Endocrine, immune, and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication. Neuropsychopharmacology 5:23-31
80. Persico AM, Schindler CW, Zaczek R, Brannock MT, Uhl GR (1995) Brain transcription factor gene expression, neurotransmitter levels, and novelty response behaviors: alterations during rat amphetamine withdrawal and following chronic injection stress. Synapse 19:212-227
81. Lynch M, Kenny M, Leonard BE (1977) The effects of chronic administration of D-amphetamine on regional changes in catecholamines in the rat brain. J Neurosci Res 3:295-300
82. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103
83. Schmidt CJ, Sonsalla PK, Hanson GR, Peat MA, Gibb JW (1985) Methamphetamine-induced depression of monoamine synthesis in the rat: development of tolerance. J Neurochem 44:852-855
84. Brown JM, Hanson GR, Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223
85. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302:497-501
86. Persico AM, Schindler CW, Brannock MT, Gonzalez AM, Surratt CK, Uhl GR (1993) Dopaminergic gene expression during amphetamine withdrawal. Neuroreport 4:41-44
87. Morgan ME, Gibb JW (1980) Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei. Neuropharmacology 19:989-995
88. Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257-262
89. Trulson ME, Cannon MS, Faegg TS, Raese JD (1987) Tyrosine hydroxylase immunochemistry and quantitative light microscopic studies of the mesolimbic dopamine system in rat brain: effects of chronic methamphetamine administration. Brain Res Bull 18:269-277
90. Broom SL, Yamamoto BK (2005) Effects of subchronic methamphetamine exposure on basal dopamine and stress-induced dopamine release in the nucleus accumbens of rats. Psychopharmacology (Berl) 181:467-476
91. Utena H, Ezoe T, Kato N, Hada H (1959) Effects of chronic administration of methamphetamine in enzymatic patterns in brain tissue. J Neurochem 4:161-169
92. Egashira T, Yamanaka Y (1993) Changes in monoamine oxidase activity in mouse brain associated with d-methamphetamine dependence and withdrawal. Jpn J Pharmacol 46:609-614
93. Herman ZS, Trzeciak H, Chrusciel TL, Kmiteciak-Kolada K, Drybanski A, Sokola A (1971) The influence of prolonged amphetamine treatment and amphetamine withdrawal on brain biogenic amine content and behaviour in the rat. Psychopharmacologia (Berl) 21:74-81
94. Tonge SR (1974) Noradrenaline and 5-hydroxytryptamine metabolism in six areas of rat brain during post-amphetamine depression. Psychopharmacologia (Berl) 38:181-186
95. Axt KJ, Molliver ME (1991) Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse 9:302-313
96. Bakhit C, Gibb JW (1981) Methamphetamine-induced depression of tryptophan hydroxylase: recovery following acute treatment. Eur J Pharmacol 76:229-233
97. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193:153-163
98. Schildkraut JJ, Watson R, Draskoczy PR, Hartmann E (1971) Amphetamine withdrawal: depression and M.H.P.G. secretion. Lancet 2:485-486
99. Maas JW, Landis DH (1968) In vivo studies of the metabolism of norepinephrine in the central nervous system. J Pharmacol Exp Ther 163:147-162
100. 3 in rat brain: identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol 17:247-254
101. 4 in the rat. Commun Psychopharmacol 3:217-223
102. Lynch MA, Leonard BE (1978) Changes in brain γ-aminobutyric acid concentrations following acute and chronic amphetamine administration and during post amphetamine depression. Biochem Pharmacol 27:1853-1855
103. Ostrander MM, Badiani A, Day HEW, Norton CS, Watson SJ, Akil H, Robinson TE (2003) Environmental context and drug history modulate amphetamine-induced c-fos mRNA expression in the basal ganglia, central extended amygdala, and associated limbic forebrain. Neuroscience 120:551-571
104. Rossetti ZL, Hmaidan Y, Gessa GL (1992) Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221:227-234
105. Weiss F, Imperato A, Casu MA, Mascia MS, Gessa GL (1997) Opposite effects of stress on dopamine release in the limbic system of drug-naïve and chronically amphetamine-treated rats. Eur J Pharmacol 337:219-222
106. Shilling PD, Kelsoe JR, Segal DS (1997) Dopamine transporter mRNA is up-regulated in the substantia nigra and the ventral tegmental area of amphetamine-sensitized rats. Neurosci Lett 236:131-134
107. Lu W, Wolf ME (1997) Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Mol Brain Res 49:137-148
108. Harlan RE, Garcia MM (1998) Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 16:221-267
109. Russig H, Pryce CR, Feldon J (2006) Amphetamine withdrawal leads to behavioral sensitization and reduced HPA axis response following amphetamine challenge. Brain Res 1084:185-195
110. Wolf ME, Sun X, Mangiavacchi S, Chao SZ (2004) Psychomotor stimulants and neuronal plasticity. Neuropharmacology 47:61-79
111. Lu W, Monteggia LM, Wolf ME (1999) Withdrawal from repeated amphetamine administration reduces NMDAR1 expression in the rat substantia nigra, nucleus accumbens and medial prefrontal cortex. Eur J Neurosci 11:3167-3177
112. Onn S-P, Grace AA (2000) Amphetamine withdrawal alters bistable states and cellular coupling in rat prefrontal cortex and nucleus accumbens neurons recorded in vivo. J Neurosci 20:2332-2345
113. McCracken CB, Patel KM, Vrana KE, Paul DL, Roberts DCS (2005) Amphetamine withdrawal produces region-specific and time-dependent changes in connexin36 expression in rat brain. Synapse 56:39-44
114. Falk MM (2000) Biosynthesis and structural composition of gap junction intercellular membrane channels. Eur J Cell Biol 79:564-574
115. Murphy CA, Russig H, Pezze M-A, Ferger B, Feldon J (2003) Amphetamine withdrawal modulates FosB expression in mesolimbic dopaminergic target nuclei: effects of different schedules of administration. Neuropharmacology 44:926-939
116. Sorensen JB (2005) SNARE complexes prepare for membrane fusion. Trends Neurosci 28:453-455
117. Gao Y, Bezchlibnyk YB, Sun X, Wang J-F, McEwen BS, Young LT (2006) Effects of restraint stress on the expression of proteins involved in synaptic vesicle exocytosis in the hippocampus. Neuroscience 141:1139-1148
118. Subramaniam S, Marcotte ER, Srivastava LK (2001) Differential changes in synaptic terminal protein expression between nucleus accumbens core and shell in the amphetamine-sensitized rat. Brain Res 901:175-183
119. Barr AM, Markou A (2005) Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 29:675-706
120. Davidson C, Gopalan R, Ahn C, Chen Q, Mannelli P, Patkar AA, Weese GD, Lee TH, Ellinwood EH (2007) Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. Eur J Pharmacol 565:113-118